{
    "name": "estramustine",
    "comment": "Rx",
    "other_names": [
        "Emcyt"
    ],
    "classes": [
        "Antineoplastics",
        "Hormones"
    ],
    "source": "https://reference.medscape.com/drug/emcyt-estramustine-342085",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X",
            "Lactation: not intended for use in women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not intended for use in women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to estradiol or nitrogen mustard",
                "Active thrombophlebitis or thromboembolic disorder, except when tumor mass is cause of thromboembolic phenomenon and benefits of therapy outweigh risk"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased risk of thrombosis, including fatal and non-fatal MI",
                "Liver dysfunction, metabolic bone disease associated with hypercalcemia, renal insufficiency",
                "History of thromoboembolic phenomenon especially associated with estrogen therapy",
                "Decreased glucose tolerance-monitor diabetics",
                "Risk of HTN-monitor BP periodically",
                "May cause fluid retention with exacerbation of CHF, peripheral edema, or conditions influenced by fluid retention, such as epilepsy, migraine, renal dysfunction",
                "May cause gynecomastia and impotence",
                "Allergic reactions, including angioedema of airway has been reported",
                "Avoid becoming pregnant"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, estramustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of estramustine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, estramustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, estramustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcium acetate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcium chloride decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcium citrate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcium gluconate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "food",
            "description": {
                "common": "food decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Esp. calcium rich foods; Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "estramustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, estramustine.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and estramustine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, estramustine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, estramustine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Breast tenderness and enlargement",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Cerebrovascular accident",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "Thrombophlebitis",
            "percent": null
        },
        {
            "name": "Pulmonary embolism",
            "percent": null
        },
        {
            "name": "Congestive heart failure",
            "percent": null
        },
        {
            "name": "Easy bruising",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Dry skin",
            "percent": null
        },
        {
            "name": "Impotence",
            "percent": null
        },
        {
            "name": "Leg cramps",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Decreased testosterone",
            "percent": null
        },
        {
            "name": "Abnormality of hepatic enzymes and",
            "percent": null
        },
        {
            "name": "or bilirubin",
            "percent": null
        }
    ]
}